Focused radiation to main tumor after chemo-immunotherapy for lung cancer
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This trial is for people with advanced non-small cell lung cancer whose tumors responded well to initial chemo-immunotherapy. Instead of giving full chest radiation, doctors will only target the main tumor to see if it can prevent regrowth with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer (the most common type of lung cancer).
- Your tumor must have shrunk or stayed the same after at least 2 cycles of chemo plus immunotherapy together.
- You need to be between 18 and 80 years old and be active enough to do daily activities (performance status 0 or 1).
- You must not have EGFR, ALK, or ROS1 gene mutations (other treatment routes work better for those).
- You cannot have had radiation to the chest before, or have serious immune-related side effects from prior immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether it is safe to skip routine radiation to the tumor bed in patients with stage III lung cancer that has responded well to immunotherapy and chemotherapy. It aims to reduce side effects while still controlling the cancer.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
This trial is testing whether giving focused radiation therapy to the main lung tumor, in addition to standard treatments like targeted therapy or chemo-immunotherapy, can help people with advanced lung cancer that has spread to many places. The goal is to see if adding this radiation can improve outcomes without causing too many side effects.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
This trial tests whether giving focused radiation to remaining spots of lung cancer (after standard treatment) can help prevent cancer from growing back. It may be an option if you have had 4-6 cycles of chemo plus immunotherapy and still have a few active spots.
This trial looks at whether giving additional targeted radiation to the chest can help people with extensive-stage small cell lung cancer after they finish standard chemo-immunotherapy. It may help control the cancer in the lung area and prevent it from coming back there.
Hear when a new Radiotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.